Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
2015; Oxford University Press; Volume: 54; Issue: 5 Linguagem: Inglês
10.1093/rheumatology/keu463
ISSN1462-0332
Autores Tópico(s)Autoimmune Bullous Skin Diseases
ResumoThere is new evidence that B-cell depletion could be an effective intervention in patients with SSc. Observational case–control study data from the European League Against Rheumatism Scleroderma Trials and Research group has suggested that rituximab therapy may reduce progression of skin thickening and lung fibrosis, especially in a subgroup with early dcSSc. These positive data remain preliminary and need to be viewed with caution, recognizing the spontaneous regression of skin thickening that may occur during early disease. In this review, we summarize the clinical evidence for the therapeutic use of rituximab in SSc as well as the basic science evidence suggesting that B cells and autoantibodies are the primary drivers of fibrosis in skin and lung tissue. We have also reviewed the parallels between SSc and the other CTDs where B-cell depletion therapy is efficacious.
Referência(s)